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DEK is required for homologous 
recombination repair of DNA 
breaks
Eric A. Smith1, Boris Gole2, Nicholas A. Willis3, Rebeca Soria4, Linda M. Starnes4, 
Eric F. Krumpelbeck1, Anil G. Jegga1, Abdullah M. Ali5, Haihong Guo6, Amom R. Meetei5, 
Paul R. Andreassen5, Ferdinand Kappes6, Lisa M. Privette Vinnedge1, Jeremy A. Daniel4, 
Ralph Scully3, Lisa Wiesmüller2 & Susanne I. Wells1,†
DEK is a highly conserved chromatin-bound protein whose upregulation across cancer types correlates 
with genotoxic therapy resistance. Loss of DEK induces genome instability and sensitizes cells to DNA 
double strand breaks (DSBs), suggesting defects in DNA repair. While these DEK-deficiency phenotypes 
were thought to arise from a moderate attenuation of non-homologous end joining (NHEJ) repair, the 
role of DEK in DNA repair remains incompletely understood. We present new evidence demonstrating 
the observed decrease in NHEJ is insufficient to impact immunoglobulin class switching in DEK 
knockout mice. Furthermore, DEK knockout cells were sensitive to apoptosis with NHEJ inhibition. 
Thus, we hypothesized DEK plays additional roles in homologous recombination (HR). Using episomal 
and integrated reporters, we demonstrate that HR repair of conventional DSBs is severely compromised 
in DEK-deficient cells. To define responsible mechanisms, we tested the role of DEK in the HR repair 
cascade. DEK-deficient cells were impaired for γH2AX phosphorylation and attenuated for RAD51 
filament formation. Additionally, DEK formed a complex with RAD51, but not BRCA1, suggesting a 
potential role regarding RAD51 filament formation, stability, or function. These findings define DEK as 
an important and multifunctional mediator of HR, and establish a synthetic lethal relationship between 
DEK loss and NHEJ inhibition.
The DNA-binding and chromatin-regulating DEK oncogene is expressed across multicellular eukaryotes and is 
highly conserved in mammals. Strong sequence conservation of the ψ SAP-SAP and C-terminal DNA binding 
domains, as well as the lack of any known DEK paralogs, suggest stringent evolutionary pressure on this gene1,2. 
However, despite extensive biochemical, cellular, and clinical investigations into the DEK protein, molecular 
functions that explain this selective pressure remain poorly understood, as does the frequent over-expression of 
DEK in human cancers3–8.
In cultured cells, DEK has functions in chromatin remodeling9–11, DNA replication9,12, and mRNA splicing13. 
Depending on the experimental system chosen, DEK loss attenuates distinct oncogenic phenotypes such as pro-
liferation14–16, survival17,18, and chemoresistance14,17,19. Dek knockout mice are viable and resistant to macroscopic 
tumor development8,20. Biochemically, there are no known enzymatic functions associated with DEK, but the pro-
tein self-multimerizes, induces positive supercoils in DNA through the ψ -SAP-SAP and C-terminal DNA binding 
domains, and preferentially binds cruciform DNA structures21–24. DEK also has roles in maintaining chromatin 
architecture9,11 and interacts with histones10,25 and chromatin modifiers11. Since the discovery of the DEK gene as 
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a DEK-NUP214 fusion protein in AML26 and the discovery of elevated DEK expression in breast3,27, colorectal5,28, 
lung4,29, and several other types of cancer1, many systems have been used to investigate the pathological conse-
quences of DEK over-expression. A prominent phenotype in cell models is the requirement of DEK for chemo-
therapy and radiation resistance. For example, expression of the DEK C-terminal domain in ataxia-telangiectasia 
fibroblasts partially restored radiation resistance, and the loss of DEK conferred sensitivity to DNA damaging 
agents in multiple cell types14,19,30. Mechanistically, our prior report found that DEK was required for optimal 
kinase activity of DNA-PK. This kinase is a key mediator of canonical non-homologous end joining (NHEJ), 
which repairs DNA double strand breaks (DSBs)31, and DEK loss correspondingly suppressed NHEJ19.
The observed NHEJ defects in DEK-deficient cells are unlikely to fully account for the severe sensitivity to 
genotoxic agents, especially DNA interstrand cross linkers and topoisomerase inhibitors14,32. This suggests addi-
tional roles for DEK in genotoxic drug tolerance and DNA repair. A common mechanism by which genotoxic 
agents induce cell death is through perturbation of replication fork progression33. A recent study determined that 
DEK attenuates DNA replication stress12 in a manner similar to RAD51 and FANCD2, factors well known for 
their function in both homologous recombination (HR) DSB repair and activities at arrested replication forks34–37.
HR requires the presence of a homologous template, often the sister-chromatid, to be used for repair, and 
is therefore largely confined to S/G2 phases of the cell cycle. By copying a homologous DNA sequence, HR is 
considered an error-free repair process that preserves genome integrity38. This signal cascade is initiated by the 
DSB sensor, ATM kinase. After localizing to a DSB, ATM autophosphorylates39,40, pATM catalyzes the phospho-
rylation of CHK2 to inhibit cell cycle progression41 and the H2AX histone to produce gamma-H2AX (γ H2AX) 
epigenetic marks on both sides of the DSB. The γ H2AX mark supports DSB repair by enhancing the recruitment 
of BRCA1 and key nucleases including the MRN complex and CtIP38,42–44. These factors coordinate DNA end 
processing into single strand DNA (ssDNA) 3′ tails38,42,43. The resulting ssDNA is initially coated by RPA, which is 
then efficiently replaced with a RAD51 filament through the combined activities of BRCA1, BRCA2, the RAD51 
paralogs, and other factors38,42. This RAD51 filament catalyzes strand invasion, complementary strand annealing, 
and the formation of a stable synaptic complex with a homologous sequence on the sister chromatid45.
While the cellular regulation and choice between DSB-repair pathways remains incompletely understood46–50, 
NHEJ and HR factors have been shown to be mutually antagonistic as one pathway tends to compensate when the 
other is compromised42,51. For example, loss of critical HR gene functions in Fanconi Anemia mutant cells results 
in enhanced dependence upon NHEJ factors52–54 while HR repair efficiency is increased following the disruption 
of essential NHEJ factors by chemical inhibition or mutation of DNA-PK51,55,56. Compromising both the NHEJ 
and HR repair pathways may be synthetic lethal to cancer cells.
In this report, we demonstrate that DEK is required for the repair of DSBs by HR. Investigation of poten-
tial DEK functions in the HR pathway revealed that the protein was important for γ H2AX activation, pro-
moted the co-recruitment of BRCA1 and RAD51 to resected ssDNA, and formed a complex with RAD51 in a 
BRCA1-independent manner. The dependence of HR on DEK expression was underscored by the synthetic lethal 
relationship between DEK loss and NHEJ inhibition. Together, these results reveal a novel, multifunctional role 
for DEK in HR.
Results
DEK loss causes apoptosis in conjunction with DNA-PK inhibitors. We have previously shown that 
DEK knockout (DEK− /− ) mouse embryonic fibroblasts (MEFs) harbor decreased NHEJ activity19. To deter-
mine the contribution of DEK to NHEJ activity in vivo, we measured the concentrations of immunoglobulins 
in DEK− /− mouse serum. Class switch recombination (CSR) from IgM to the IgA and IgG classes of immu-
noglobulins is an NHEJ-dependent process31, but DEK− /− mice were fully competent in producing all classes 
of immunoglobulins (Fig. 1a). This data suggests the residual NHEJ activity in the knockout mice is sufficient 
for CSR under physiologically normal in vivo conditions, despite the sensitivity of DEK-deficient cells to DNA 
damaging agents14,19. To determine if DEK-deficient cells require NHEJ for survival, we examined the need for 
NHEJ by inhibiting the upstream kinase, DNA-PK. We utilized two well-established DNA-PK inhibitors, NU7026 
and NU7441, to prevent DNA-PKcs autophosphorylation and activation57–60. DEK− /− MEFs treated with the 
DNA-PK inhibitor NU7026 displayed dramatically more cell death than wild-type (DEK+ /+ ) or untreated sam-
ples (Fig. 1b). Analysis of cleaved caspase 3 positive cells by flow cytometry revealed that the inhibitors were 
sufficient to induce a significant and specific 2–3 fold increase in apoptosis in the DEK− /− cells in the absence of 
exogenous DNA damaging agents (Fig. 1c). Similar experiments in HeLa cells infected with a well-characterized 
DEK knockdown versus control adenovirus vector (AdDEKsh versus AdGFP)18 revealed a similar 2-fold increase 
in apoptosis after treatment with either DNA-PK inhibitor, NU7026 or NU7441 (Fig. 1d,e). These data suggest 
that DEK-deficient cells, despite their attenuated NHEJ activity19, rely significantly on the remaining NHEJ for 
survival.
DEK is required for HR DSB repair. Several reports have described an antagonistic relationship between 
HR and NHEJ mechanisms of DSB repair46,55,61, and it is generally thought that loss of one pathway will result in 
compensation by the remaining repair modality53,55,56. Given the dependence of DEK-deficient cells on NHEJ and 
their inherent sensitivity to chemotherapeutics, we hypothesized that HR may be compromised in DEK− /− cells. 
To test this we first utilized two established episomal HR reporter systems56,62. These vectors harbor two defunct 
EGFP genes, the first bearing an I-SceI meganuclease cleavage site and the second bearing a truncated gene 
sequence (Fig. 2a). Co-transfection with an I-SceI expression vector induces a DSB that, when repaired by HR, 
generates a functional EGFP gene. Both the HR-EGFP/5′ EGFP and pHPRT-DR-GFP reporters demonstrated 
a remarkable and severe loss of HR efficiency in DEK− /− MEFs (Fig. 2b). To compare the effects of DEK loss 
on chromosomal HR repair following direct or replication-dependent DSB induction, we utilized the recently 
published 6xTer-HR reporter technology63. The 11CO/47 mouse embryonic stem (mES) cell line bearing a single 
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copy of the 6xTer-I-SceI-GFP reporter cassette integrated at the Rosa26 locus quantifies HR either at an I-SceI 
endonuclease-induced DSB or at an adjacent Tus/Ter-induced stalled replication fork. Fork stalling is induced by 
Tus protein binding to an array of six Ter elements, forming a physical barrier that impedes approaching replica-
tion fork progression63 (Fig. 2c). Using this system, we quantified the impact of DEK depletion on error-free short 
tract gene conversion (STGC), producing GFP+RFP− cells, and error-prone long tract gene conversion (LTGC), 
producing GFP+RFP+ cells through duplication and thus proper alignment of two synthetic exons of RFP. After 
co-transfecting Dek siRNA (Fig. 2D) and I-SceI, we found that siDek treated cells were significantly compromised 
for both total HR and STGC, and LTGC followed the same trend (Fig. 2e). This decrease was similar in magni-
tude to loss of the BRCA proteins64, but not as severe as RAD51 deficiency63. However, there was no significant 
decrease in STGC, LTGC, or total HR with Tus-induced DNA replication fork stalling (Fig. 2f). This suggests 
Figure 1. DEK loss causes apoptosis in conjunction with DNA-PK inhibitors. (a) Mouse serum 
immunoglobulin levels were quantified by ELISA (n = 3). (b) Representative live-cell images of mouse 
embryonic fibroblasts (MEFs) 72 hrs post treatment with a DNA-PK inhibitor (10x magnification).  
(c) DEK− /− MEF cells display increased apoptosis following 48 hr treatment with NU7026. (paired t-test, 
n = 6, mean ± SEM) (d) Hela cells were pre-treated with adenovirus for 24 hr prior to treatment with two 
different DNA-PK inhibitors. Representative images collected after incubating with drug for 48 hrs. (e) Both 
drugs demonstrated a significant increase in apoptosis at this time point. (paired t-test, n = 3, mean ± SEM).
www.nature.com/scientificreports/
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that DEK, unlike most HR factors63, is dispensable for replication fork associated repair but required for efficient 
repair of DSBs.
DEK is necessary for the activation of γH2AX after ionizing radiation. To understand how DEK 
functions in HR, we examined the consequences of DEK loss at successive steps in the repair pathway following 
irradiation (IR) mediated DSB induction. For these studies we used DEK− /− MEFs and AdDEKsh-infected HeLa 
cell systems, whose cell cycle progression was reported comparable to that of their respective DEK-proficient 
controls18,19. Beginning with the relevant upstream DNA damage sensor kinase, we found that ATM was strongly 
autophosphorylated in AdDEKsh-treated HeLa cells (Supplementary Fig. S1a) and functional as indicated by 
phosphorylation of pCHK2 T68, an ATM substrate (Supplementary Fig. S1b). Surprisingly, γ H2AX phosphoryl-
ation was not enhanced in the AdDEKsh HeLa cells despite robustly activated pATM (Supplementary Fig. S1a). 
This held true and was even more severe in the DEK− /− MEF system where DEK was required to increase γ 
H2AX phosphorylation above baseline by immunofluorescence (IF) (Fig. 3a). Both the total number of cells 
harboring γ H2AX foci and the average number of foci per cell were severely attenuated from 3–24 hours after 
irradiation (Fig. 3b,c). These results were also confirmed by western blot analysis in MEFs and in DEK knock-
down C33A cancer cells (Fig. 3d,e), suggesting that DEK is an important general contributor to γ H2AX phospho-
rylation in IR-treated cells.
Loading of RAD51 onto RPA-protected DNA is significantly reduced. DSB end-processing 
occurs downstream of the pATM-γ H2AX signal amplification feedback loop and generates ssDNA overhangs 
that are bound and protected by RPA. End processing is coordinated by several factors, including the MRN 
Figure 2. DEK is required for HR DSB repair. (a) Schematic of two episomal HR reporter plasmids. After 
co-transfection with an I-SceI plasmid, the mutant GFP gene (light green) site indicated by double arrows is 
cleaved. The circle represents the corresponding region of homology to the I-SceI site, and the X represents 
gene truncations. Expression of functional GFP (dark green) is dependent on HR repair of the cleaved plasmid. 
(b) GFP+ FACs quantification of repair frequency of the constructs in (A). (Mann-Whitney test, n = 12 for 
HR-EGFP/5′ EGFP and n = 5 for pHPRT-DRGFP, mean ± SEM) (c) Schematic of the 6xTer vector. Tus-Ter 
binding induces replication fork stalling at the 6xTer array (red hourglass) while I-SceI creates a DSB at the 
location indicated by the double arrows. HR repair triggered by I-SceI or Tus expression results in short tract 
gene conversion (STGC, GFP+ RFP−), or long-tract gene conversion (LTGC) through the duplication and 
proper alignment of two synthetic RFP exons allowing RFP expression by alternative mRNA splicing (GFP+ 
RFP+). (d) Western blot analysis of 6xTer mES cells after siDek treatment. (e) Quantification of total HR repair 
(STGC + LTGC) and individual STGC and LTGC repair FACs following I-SceI transfection. (Unpaired Welch’s 
t test, n = 6, mean ± SEM) (f) STGC and LTGC HR repair following Tus transfection. (Unpaired Welch’s t test, 
n = 6, mean ± SEM).
www.nature.com/scientificreports/
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Figure 3. DEK is necessary for the activation of γH2AX after ionizing radiation. (a) MEFs were treated 
with 10 Gy of gamma ionizing radiation (IR) and stained for γ H2AX. Representative cross sections from z-stack 
confocal images are shown. (b) Quantification of cells with > 10 γ H2AX foci in (A). At least 50 cells per time 
point were counted in each biological replicate, and all foci within the z-stack were quantified.  
DEK− /− MEFs were unable to activate γ H2AX above baseline after irradiation. (paired t-test, n = 3, 
mean ± SEM). (c) Quantification of the average total number of γ H2AX foci in each cell from (A). (paired 
t-test, n = 3, mean ± SEM) The number of foci per cell remained unchanged in DEK− /− MEFs after 
irradiation. (d) Western blot analysis of γ H2AX in MEFs at 6 hs following irradiation with 10 Gy. (e) Western 
blot analysis of C33A human cancer cells infected with adenovirus 48 hr prior to receiving 10 Gy IR (see also 
Supplementary Fig. S1).
www.nature.com/scientificreports/
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complex and BRCA143,44. Chromatin fractionation of HeLa cells revealed that chromatin recruitment of MRE11 
and NBS1, components of the MRN complex, as well as BRCA1 were not affected by DEK status following IR 
(Supplementary Fig. S2a,b). Following end-processing, BRCA1 both co-localizes with and is necessary for robust 
RAD51 IF foci development43. Through assessing the quality and quantity of these foci, we determined whether 
DEK loss disrupts RAD51 loading onto RPA-bound ssDNA43. Since our BRCA1 antibody does not detect murine 
BRCA1, we performed these experiments in HeLa cells. DEK knockdown in HeLa cells had a mild, but sta-
tistically significant delay in BRCA1-RAD51 foci formation at 3 hours following IR (Fig. 4a,b) with no differ-
ence in individual BRCA1 or RAD51 foci formation at any time point (Supplementary Fig. S3). By 6 hours the 
co-localization of BRCA1 and RAD51 foci was indistinguishable from control cells. To determine if the delay 
in RAD51-BRCA1 co-localization correlated with impaired RAD51 loading onto RPA-protected ssDNA, we 
also determined the kinetics of RAD51 localization to RPA foci. In line with the delay with BRCA1-RAD51 
co-localization, we found a significant decrease of RAD51-RPA2 co-localized foci at 3 and 6 hours post irradia-
tion (Fig. 4c). A 24-hour time course in DEK+ /+ and DEK− /− MEFs revealed that RAD51 loading was simi-
larly attenuated (Fig. 4d,e). There was no difference in RAD51 foci quantity or quality (Supplementary Fig. S4a), 
but RPA2 foci were generally smaller in DEK− /− cells. DEK− /− cells also retained persistent RPA2 foci at later 
time points, suggesting a DNA repair defect (Supplementary Fig. S4b). In summary, DEK-deficient cells have 
a small reduction in the recruitment of RAD51 to BRCA1 foci, which results in a mild attenuation of RAD51 
loading on RPA-coated ssDNA.
DEK interacts with RAD51. While RAD51 loading was not dramatically affected by DEK loss, physical 
DEK interactions with the RAD51 recombinase were possible. To test this, pMIEG His-FLAG-DEK expressing 
HeLa cells were left untreated or received 1 mM hydroxyurea (HU) for 15hrs to induce replication fork stalling 
and a low level of DSB generation as published previously65, prior to FLAG immunoprecipitation (IP). Under 
these conditions, we found that RAD51 complex formation occurred with His-FLAG DEK (Fig. 5a). Validation of 
the complex was performed by IP of endogenous DEK and reverse IP of RAD51 in parental HeLa cells (Fig. 5b,c). 
No BRCA1 interaction with DEK was observed (Fig. 5b), suggesting that DEK forms a separate complex from the 
standard BRCA-RAD51 homologue apparatus. The DEK-RAD51 complex was also observed in untreated and 
irradiated cells. Thus, DEK interacts with the HR recombinase RAD51 in the presence or absence of exogenous 
DNA damage (Supplementary Fig. S5).
Discussion
Herein we demonstrate that DEK is required for the repair of DSBs by HR, and regulates multiple steps in the HR 
cascade by promoting γ H2AX activation, enabling robust RAD51 loading, and forming a complex with RAD51 
(Fig. 5d). This importance of DEK in HR was further underscored by the exquisite sensitivity of DEK-deficient 
cells to NHEJ loss through DNA-PK inhibition. In summary, this is the first report to describe DEK as a HR factor 
and to identify a synthetic lethal relationship that exists between DNA-PK inhibition and DEK loss.
According to the 6xTer reporter assays (Fig. 2c–f), DEK appears to be required for HR only in the context 
of conventional DSBs, wherein DEK-deficient cells had a similar HR deficiency to BRCA1 loss63, but not in the 
context of stalled replication forks. However, this selectivity differs when DEK activities are compared to those 
of BRCA1, BRCA2, and RAD51, factors which are required for the HR repair triggered by both I-SceI induced 
DSBs and Tus-stalled replication forks63. Based on these observations, it is likely that DEK is expendable for 
replication-associated HR repair, but this by no means precludes non-HR functions at stalled replication forks. 
Indeed, published DNA fiber assays have elegantly shown that DEK can promote stalled replication fork restart 
and reduce γ H2AX response to DNA replication stress12.
Differential γ H2AX responses to irradiation (Fig. 3) versus chemotherapy-induced damage12,19 lends fur-
ther support to a model where DEK is specifically required for HR repair of DSBs. Previous studies have found 
that loss of DEK enhances γ H2AX activation following treatment with replication fork stalling agents12,19. While 
similar pATM activation was observed in response to stalling or irradiation, γ H2AX phosphorylation was spe-
cifically not engaged after IR exposure. This suggests that DEK is specifically required for ATM-H2AX signal 
transduction under conditions of DSBs. While it is known that γ H2AX is not strictly required for HR, its loss can 
slow the kinetics of the pathway and lead to a moderate decrease in repair efficiency44,66. Thus, the attenuation of 
BRCA1-RAD51 and RAD51-RPA2 foci co-localization (Fig. 4) is likely a consequence of failed γ H2AX activa-
tion. These pulldown results, in which DEK interacted with RAD51 in a BRCA1-free complex (Fig. 5), further 
support this hypothesis as they suggest DEK is not part of the BRCA1-Palb2-BRCA2-RAD51 complex that facil-
itates RAD51 loading. However, we cannot presently rule out weak interactions or a role for BRCA in promoting 
the DEK-RAD51 interaction. Also, since these interactions were identified and confirmed in cervical cancer cells, 
it is uncertain if the DEK-RAD51 complex is a component of normal cell biology or specific to cancer cells.
Taken together these data support a model in which DEK has two distinct roles in the repair of DSBs by 
HR. First, DEK has an important function in γ H2AX activation by ATM, but this is unlikely to be sufficient for 
the degree of HR deficiency observed in DEK-deficient cells44,66. Therefore, DEK must have a second function 
involving the DEK-RAD51 complex. With regard to a possible mechanism of action, DEK might play an early 
role in homologous recombination by supporting the initial formation of the RAD51-DNA filament. However, 
since BRCA1 and BRCA2 play key roles in this step and, since BRCA1 was not detectable in the DEK-RAD51 
complex (Fig. 5b), we do not favor this scenario. Based on previous structural and cell-free studies, DEK bind-
ing to DNA stimulates self-multimerization and potential interactions with other proteins22,67,68. Furthermore, 
DEK preferentially binds cruciform over conventional linear DNA structures24, and harbors three putative DNA 
binding motifs67,68. Thus, one possible scenario is that DEK interacts with both the invading RAD51 filament and 
www.nature.com/scientificreports/
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Figure 4. Loading of RAD51 onto RPA-protected DNA is significantly reduced. (a) HeLa cells were infected 
with 10 IU of adenovirus 48 hr prior to receiving 10 Gy and collection at 3, 6, and 12 hr post irradiation. 
Cells were subjected to immunofluorescence for BRCA1 (red) and RAD51 (far red, pseudo-colored green). 
Shown are representative images from untreated, 3 and 6hrs post irradiation. (b) Quantification of the co-
localized foci from (A). Cells with ≥ 3 overlapping BRCA1 and RAD51 foci were counted as positive, and > 
100 cells were counted in three biological replicate experiments. (student’s t-test, n = 3, mean ± SEM, see also 
Supplementary Fig. S3). (c) HeLa cells were treated, collected, stained for RPA2 and RAD51 and quantified 
as in (A) and (B). (student’s t-test, n = 4, mean ± SEM, see also Supplementary Fig. S4). (d) To examine time 
points beyond 12 hrs, MEF cells were treated with 10 Gy, harvested at 3, 6, 12, 18, and 24 hr post treatment, 
and subjected to immunofluorescence for RPA2 (red) and RAD51 (far red, pseudo-colored green). Shown are 
representative images from untreated and 6 hr after irradiation. (e) Quantification of the co-localized foci from 
(D) performed as in (C).
www.nature.com/scientificreports/
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the sister chromatid to stabilize resulting D-loop structures. Such activities can now be readily explored through 
established biochemical assays69.
Since this is the first report to establish a role for DEK in HR, our work opens up multiple avenues for future 
study. At the molecular level, mechanisms whereby DEK promotes γ H2AX activation specifically at DSBs and the 
nature and function of the complex with RAD51 remain unclear. Secondly, in the absence of known DEK homo-
logues, detailed studies of the evolutionary history and origin of DEK are lacking despite its strong conservation 
across mammals and presence in plants. Interestingly, DEK is absent in bacteria and yeast, wherein mechanisms 
of HR are well described. It is possible that the early multicellular eukaryotes required a novel chromatin regulator 
to stabilize their increasingly complex genomes during DNA repair. Considering its role in chromatin modifi-
cation and ATM-mediated γ H2AX activation, its affinity for RAD51 and DNA structures similar to Holliday 
junctions, and its ability to stabilize DNA breaks for in vitro DNA ligation, DEK is a likely candidate to fill this 
niche1,24.
Still, further investigations into the activities of DEK in HR and NHEJ repair will remain important for deep-
ening our knowledge of the evident evolutionary pressure on DEK and HR, understanding the multiple activities 
of DEK in HR, and for the development of small molecule inhibitors to target relevant functions of this oncogene. 
In support of these future therapeutic efforts, we identified a synthetic lethal relationship between DEK loss 
and canonical NHEJ inhibition, as well as a cellular phenotype that can be assessed for DEK inhibition in vivo. 
This is important as DEK is largely dispensable for cell division, and DEK− /− mice are healthy and viable12,18,20, 
suggesting a high therapeutic index for a potential anti-DEK drug. Thus, it is conceivable that DEK overexpress-
ing tumors may regress without a need for adjuvant radiation or traditional chemotherapy if substituted for 
tumor-specific co-targeting of DEK and DNA-PK.
Materials and Methods
Cell culture, adenoviral infections, and viral transductions. HeLa and C33A cells were grown in 
Dulbecco’s Modified Essential Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and anti-
biotics. MEFs, generated previously19, were cultured in DMEM with 10% heat inactivated FBS, 100 μ M MEM 
non-essential amino acids, 0.055 mM β -mercaptoethanol (BME), 2 mM L-glutamine, and 10 μ g/ml gentamy-
cin. Mouse embryonic stem (ES) cells were grown in ES media on fibroblast or gelatin substrate as previously 
described63. To induce DNA damage, cells were treated with γ -IR from a 137Cs source or 1 mM hydroxyurea (HU). 
Both 40 μ M NU7026 and 2 μ M NU7441 (Tocris, Bristol, UK) were used to specifically inhibit DNA-PK as previ-
ously published59,70. DEK knockdown was accomplished using the adenoviral AdDEKsh as compared to control 
Figure 5. DEK interacts with RAD51 and is essential for multiple functions in HR DSB repair. (a) A 
FLAG IP performed in HeLa cells expressing His-FLAG tagged DEK, both in untreated and samples treated 
with 1 mM HU for 17 hrs. This identified RAD51 as a DNA-independent interacting factor. (b) RAD51 also 
co-immunoprecipitated with DEK in untransduced parental HeLa cells. (c) Reverse pulldown of RAD51 in 
parental HeLa cells confirmed DEK as an interacting partner. (d) DEK is required for successful HR of DSBs 
and functions at multiple levels in the repair cascade.
www.nature.com/scientificreports/
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AdGFP vectors at 10 infectious units (IU) per cell for 48 hr prior to IR treatment, as described previously18. The 
pMIEG His-FLAG-DEK retroviral vector was described recently71, and cells were transduced with virus for 24 hrs 
prior to sorting for GFP positive cells on a BD-FACSAria II flow cytometer.
Serum Immunoglobulin ELISA Assays. Dek+ /+ and Dek− /− littermate mice were born from hete-
rozygous crosses on a mixed C57Bl6/S129 background as previously described20. Usage and handling of mice 
was performed with the approval of the Cincinnati Children’s Institutional Animal Care and Use Committee 
and complied with institutional, state, and federal guidelines and regulations as well as AAALAC accreditation 
standards. All mice were housed in specific pathogen free housing with ad libitum access to food and water. Blood 
was obtained by cardiac puncture of three DEK+ /+ and three DEK− /− mice. To measure immunoglobulin (Ig) 
in the blood serum by ELISA, plates were coated with the following Southern Biotechnology Associates antibod-
ies (Birmingham, AL, USA): anti-mouse IgM (no. 406501), IgA (no.556969), or IgG (no. 1030-01), and Ig was 
detected with horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG1 (no. 1070-05), IgG3 (no. 1100-
05), IgG2a (no.1080-05), IgG2b (no. 1090-05), IgA (no. 1040-05), or IgM (no. 1020-05). In all cases, wells were 
developed with the Ultra TMB peroxidase substrate system (Thermo Scientific) and OD was measured at 450 nm 
using a Fluostar Omega microplate reader (BMG-Labtech, Ortenberg, Germany).
Cleaved caspase 3 flow cytometry. Cells were trypsinized, fixed in 4% PFA for 10 min at 37 °C, permea-
bilized in 90% ice-cold methanol for 30 min, and incubated with the cleaved caspase 3 cell signaling antibody for 
1 hr. Analysis was performed on a BD FACSCanto II instrument.
DNA repair reporter assays. MEFs were co-transfected with 2 μ g of HR-EGFP/5′ EGFP, pHPRT-DR-GFP, or 
an EGFP expressing plasmid (transfection control) and 2 μ g pCMV-I-SceI using Fugene HD transfection reagent 
(Roche, Penzberg, Germany) prior to a 48 hr incubation62. Cells were collected and analyzed for EGFP expression 
by flow cytometry. Analysis of chromosomal HR repair was conducted using mouse ES cells bearing a single copy 
knock-in of the 6xTer-HR reporter cassette targeted to the Rosa26 locus63. For the 6xTer-HR reporter cells, 1.6 × 105 
cells were cotransfected in suspension with 0.35 μ g empty vector, pcDNA3β -myc NLS-Tus, or pcDNA3β -myc 
NLS-I-SceI, and 20 pmol ONTargetPlus-smartpool, (Dharmacon, Lafayette, CO), siLuc (p-002099-01-20), 
or siDek (M-050260-00-0005) as described previously63. Transfected cells were analyzed by flow cytometry 
72 hrs post transfection using a Becton Dickinson LSRII. GFP+ frequencies were measured in duplicate samples, 
3–6 × 105 total events were scored. Repair frequencies presented are corrected for background events and for 
transfection efficiency (60–85%). Transfection efficiency was measured by parallel transfection with 0.05 μ g wild 
type GFP expression vector, 0.30 μ g control vector and 20 pmol siRNA.
Western blot analysis. Cell lysates were generated by lysis in NETN buffer (50 mM Tris-HCl pH = 7.4, 
250 mM NaCl, 5 mM EDTA, 0.1% NP-40, 10 mM NaF, 200 μ M Na2VO3, 0.5 mM PMSF, and 1x protease inhibitor 
cocktail) on ice for 30 min. Non-soluble debris was precipitated by a 5 min 12000 rpm spin at 4 °C and discarded. 
Lysate was treated with 4x loading buffer (0.5 M Tris-HCl pH 6.8, 277 mM SDS, 40% glycerol, bromophenol 
blue, 4% 2-mercaptoethanol), ran on a 10% SDS-PAGE gel, and transferred onto a PVDF membrane for 1–2 hr 
at 500 mA. The following Santa Cruz (Dallas, TX, USA) antibodies were used: BRCA1 (sc-6954) and RAD51 
(sc-8349 and in-house aliquot B32). The following Cell Signaling (Danvers, MA, USA) antibodies were used: 
ATM (2873), GAPDH (5174), Chk2 (2662), pChk2 T68 (2661), Chk1 (2345), and pChk1 S345 (2341). Other anti-
bodies included DEK (610948 BD Bioscience, San Jose, CA, USA), DEK (16448-1-AP, Protein Tech, Rosemont, 
IL, USA), DEK (in-house K-877)72, DNA-PKcs (ab1832, Abcam, Cambridge, MA, USA), pDNA-PKcs S2056 
(ab18192), pATM S1981 (AF1655, R&D Systems, Minneapolis, MN), γ H2AX (05-636, Millipore, Darmstadt, 
Germany), MRE11 (GTX70212, genetex, San Antonio, TX, USA), and NBS1 (NB100-143SS, Novus Biologicals, 
Littleton, CO, USA).
Immunofluorescence microscopy. 1–5 × 105 cells were plated onto poly-d-lysine treated coverslips and 
allowed to attach prior to adenovirus infection and/or drug treatment. To stain, coverslips were fixed in 4% 
paraformaldehyde, antigens retrieved with a 0.2% Triton x-100 PBS solution, and cells blocked with PBS plus 
5% normal goat serum and 0.3% Triton X-100. Antibody dilutions are as follows: BRCA1 (sc-6954), γ H2AX 
1:1000 (05-3636, Millipore), RPA2 1:300 (ab2175), RAD51 1:500 (sc-8349), goat anti-mouse Alexa Fluor 568 
1:500 (A-11004, ThermoFischer Scientific, Waltham, MA), and goat anti-rabbit Alexa Fluor 633 1:500 (A-21070). 
Nuclei were counterstained with DAPI ProLong Gold (P-36931, Life Technologies). RPA and RAD51 foci were 
captured on a Carl Zeiss Apotome instrument, and foci within 100 cells counted per time point per replicate. 
BRCA1, RAD51, and RPA foci counts were performed by eye due to background signal from the antibodies. High 
resolution images were imaged on an inverted Nikon A1R GaAsP confocal microscope. Whole cell γ H2AX foci 
were also collected on the confocal microscope using z-stacks and were quantified using Imaris 6 (Bitplane AG, 
Zurich, Switzerland).
Chromatin fractionation. Chromatin fractionation was performed as described previously73 according to 
the schematic in Fig. 3d. Briefly, HeLa cells were infected with AdGFP or AdDEKsh 48 hr prior to receiving 
10 Gy of IR. Six hours following IR, cells were counted to ensure equal numbers of cells per sample. Cell lysis 
and nuclear isolation was performed in a wash buffer (10 mM PIPES pH = 7.0, 1 mM EGTA, 0.1 M NaCl, 0.3 M 
sucrose, 0.5 M NaF, 0.5 mM Na3VO4, and 1x protease inhibitor cocktail) plus 1% Triton X-100. Serial separation 
of the precipitated nuclear fraction was performed first by treatment with wash buffer + 20 U DNAseI (AM2235, 
ThermoFischer Scientific), followed by a 5 min incubation with wash buffer + 0.5 M (NH4)SO4 on the resulting 
pellet. The resulting fractions were treated with 4x loading buffer.
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Immunoprecipitation (IP). Subconfluent cells were treated with or without 1 mM HU for 15hrs. Cells were 
homogenized in lysis buffer (10 mM HEPES, pH = 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM PMSF, 0.5 mM DTT, 
1 mM NaVO3, 10 mM NaF, and 1x Sigma P5955 protease inhibitor cocktail), and the nuclear pellet was lysed in a 
nuclear lysis buffer (20 mM HEPES pH = 7.9, 400 mM NaCl, 1% Triton X-100, 0.1% NP-40, 10% Glycerol, 0.5 mM 
PMSF, 0.5 mM DTT, 1 mM NaVO3, 10 mM NaF, and 1x protease inhibitor cocktail) on ice. After ultracentrifu-
gation, pMIEG and pMIEG His-FLAG-DEK supernatants were loaded onto anti-FLAG M2 affinity gel (A2200, 
Sigma, St. Louis, MO, USA). Parental cell supernatants were pretreated with antibodies for 1 hour prior to loading 
onto Protein A sepharose beads. For both IP experiments, lysates were treated with either 50 μ g/ml ethidium 
bromide (EtBr) or 125 U of benzonase (E8263, Sigma) plus 2 mM MgCl2 as controls. After incubating overnight 
at 4 °C, the beads were washed, and the IP products collected by boiling in 2x Laemmli Buffer (12.5 mM Tris-HCl, 
pH = 6.8, 20% Glycerol, 4% SDS, 0.004% Bromophenol Blue, 10% 2-β -mercaptoethanol).
Statistical Methods. Statistics were performed using Graphpad Prism 6 software (Graphpad Software Inc., 
San Diego, CA). Significance is indicated by asterisks (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001), and the 
number of independent biological replicates and type of analysis is indicated in the Fig. legends.
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